Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Filings indexed 788 across all filing types
Latest filing 2014-01-07 Board/Management Inform…
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 31, 2013. It includes detailed announcements about employment agreements with key executives, appointment and retirement of directors, and adoption of a cash bonus plan. The content focuses on changes in the company's board of directors and senior management, as well as executive compensation arrangements. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy solicitation or voting results announcement. The primary focus is on management and board changes and related agreements, which fits the Board/Management Information category (MANG). The document length is over 12,000 characters, indicating it is the full report, not just an announcement of a report. Therefore, the correct classification is MANG with high confidence.
2014-01-07 English
Director's Dealing 2013
Director's Dealing
2013-12-12 English
Director's Dealing 2013
Director's Dealing
2013-12-12 English
Director's Dealing 2013
Director's Dealing
2013-12-12 English
Director's Dealing 2013
Director's Dealing
2013-12-12 English
Director's Dealing 2013
Director's Dealing
2013-12-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.